Detail of the clinical trial

Title of the trial A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy
EudraCT number 2009-012518-39
Protocol number OMB112517
Sponsor Novartis Pharma Service AG, Lichtstrasse 35, CH-4056 Basel, Switzerland
Indications Hemato-oncology
Diagnosis chronic lymphocytic leukemia (CLL)
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2010
Date of approval by Institute (SÚKL) 17.2.2010
Date of approval by EC 3.3.2010
Date of initiation CT in ČR 6.10.2010
Date of ending CT in ČR 7.2.2018
Notice
Sites Nemocnice Pelhřimov-Odd. hematologie a transf.
Hematoonkolog. klin. FN Olomouc
Interní hematoonkologická klinika, FN Brno
I. interní klinika, VFN, Praha 2 (discontinued)
2. interní klinika oddělení klinické hematologie, FN Hradec králové
Oddělení klinické hematologie, FN KV, Praha 10 (discontinued)

‹‹ Back to list